Navigation Links
Uroplasty to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York
Date:11/4/2008

MINNEAPOLIS, Nov. 4 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (Amex: UPI) announced today that it will present at the Rodman & Renshaw 10th Annual Healthcare Conference on Monday, November 10, 2008 at the New York Palace Hotel in New York City. Dave Kaysen, President and Chief Executive Officer and Medi Jiwani, Vice President and Chief Financial Officer will discuss the Company's business strategy and historical financial performance at 4:55 p.m. Eastern Time.

Attendance at the conference is by invitation only. A live audio webcast of Uroplasty's presentation may be accessed through the Company's website at http://www.uroplasty.com. An archived replay of the presentation will be available after the live presentation, and can also be accessed at http://www.uroplasty.com.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our primary focus is the continued commercialization of our Urgent PC system, which we believe is the only FDA-approved minimally invasive nerve stimulation device designed for office-based treatment of urinary urgency, urinary frequency and urge incontinence - symptoms often associated with overactive bladder. We also offer Macroplastique(R) Implants, an injectable bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. Please visit Uroplasty, Inc. at http://www.uroplasty.com.

For Further Information:

Uroplasty, Inc.

David Kaysen, President and CEO, or

Medi Jiwani, Vice President, CFO, and Treasurer,

952.426.6140

EVC Group

Dahlia Bailey (Investors)

415.896.5862

Steve DiMattia/Chris Gale (Media)

646.201.5445


'/>"/>
SOURCE Uroplasty, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007
2. Uroplasty to Host Third Quarter Conference Call on February 11
3. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Global Healthcare Conference
4. MannKind to Present at the Rodman & Renshaw Annual Global Investment Conference
5. RainDance Technologies to Present Workshop on Sequence Enrichment Using Innovative Microdroplet-Based Solutions at ASHG 2008
6. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
7. RainDance Technologies to Present Sequence Enrichment Using Droplet-Based Microfluidics Workshop at ASHG 2008
8. SCOLR Pharma, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
9. Nile Therapeutics to Present at Two Upcoming Investor Conferences
10. Arno Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
11. Top-Line Preliminary Data From Phase II/III Study of Cortheras Relaxin in Acute Heart Failure to be Presented in Satellite Symposium at AHA Scientific Sessions 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... GUELPH, ON , June 27, 2016 /PRNewswire/ - BIOREM ... it has been advised by its major shareholders, Clean ... LP, United States based venture ... common shares of Biorem (on a fully diluted, as ... for the disposition of their entire equity holdings in ...
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the ... today the Clinical Reach Virtual Patient Encounter CONSULT module which enables both ... physician and clinical trial team. , Using the CONSULT module, patients and physicians can ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/15/2016)... DUBLIN , April 15, 2016 ... of the,  "Global Gait Biometrics Market 2016-2020,"  report ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait ... CAGR of 13.98% during the period 2016-2020. ... movement angles, which can be used to compute ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
Breaking Biology News(10 mins):